Drugs / MASCT-I
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04074564 | Nov 2019 → Aug 2024 | sarcoma | HRYZ Biotech Co. | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03393416 | Apr 2018 → Jul 2020 | gastric cancer | HRYZ Biotech Co. | Unknown | No outcome recorded |
| Phase 1 | NCT03034304 | Feb 2017 → Nov 2023 | cancer | HRYZ Biotech Co. | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02858232 | Aug 2016 → Oct 2018 | cancer | The First People's Hospital of Lianyungang | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06277154 | Feb 2024 → Feb 2026 overdue | angiosarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, fibrosarcoma +7 | HRYZ Biotech Co. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MASCT-I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06277154 ↗ |
| Known as | Multi-Antigen Stimulated Cell Therapy-I Injection | “Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) is a sequential immune cell therapy.” NCT04074564 ↗ |
| Modality | Cell therapy | “dendritic cells(DC) was induced from autologous peripheral blood” NCT02858232 ↗ |
| Route | Intravenous | “cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28” NCT02858232 ↗ |